Draft:Deutivacaftor
Cystic fibrosis treatment drug
From Wikipedia, the free encyclopedia
Deutivacaftor is a deuterated analogue of the cystic fibrosis drug ivacaftor. It is sold only as part of the combination product vanzacaftor/tezacaftor/deutivacaftor, sold under the brand name Alyftrek. It acts as a CFTR potentiator.[1]
Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit or make changes to this draft, simply click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about either yourself or your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Boghog (talk | contribs) 32 days ago. (Update) |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H28N2O3 |
| Molar mass | 392.499 g·mol−1 |
| 3D model (JSmol) | |
| |
